Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Dynavax Technologies Corp.
Headquarters: Emeryville, CA, United States of America
Website: http://www.dynavax.com
Year Founded: 1996
Status: Public
Industry Sector: HealthTechnology
CEO: Ryan Spencer
Number Of Employees: 405
Enterprise Value: $1,243,385,880
PE Ratio: 77.96
Exchange/Ticker 1: NASDAQ:DVAX
Exchange/Ticker 2: N/A
Latest Market Cap: $1,689,847,040
BioCentury | May 2, 2024
Data Byte
Four PDUFA dates coming in May
BMS awaits decisions on two new indications for Breyanzi; therapies from Ascendis, Dynavax also up for approvals
BioCentury | Aug 31, 2023
Finance
R&D spending for growth
Back to School 2023: Across 17 high-growth companies, average premarket R&D spend is 73% of operating expenses
BioCentury | Aug 31, 2023
Finance
Formulas for success from biotechs that leaped in value despite the downturn
Back to School 2023 identifies four themes among 17 companies that jumped a tier or increased their market cap over 200%
BioCentury | Jun 24, 2022
Regulation
June 23 Quick Takes: FDA unveils neurogenerative disease action plan
Plus FDA places hold on Sarepta DMD trial and updates from Novartis, uniQure, DermBiont, Valneva and more
BioCentury | Apr 23, 2022
Product Development
COVID roundup: CureVac says low-dose bivalent vaccine effective in mice
Plus updates from Clover, Selva and ImmunoPrecise Antibodies
BioCentury | Nov 3, 2021
Management Tracks
O’Shaughnessy named acting chief scientist at FDA
Woollett joins Samsung Bioepis, Acadia, Aadi, Passage Bio and more
BioCentury | Oct 27, 2021
Finance
Bain commits $300M to advance Cardurion’s CV programs
Bain Capital Life Sciences makes first big splash from new $1.9B third fund
BioCentury | Oct 22, 2021
Management Tracks
New board chairman at Dynavax
Plus: Arcturus, BioDelivery, Landmark Bio, Vitrolife, Novome and more
BioCentury | Aug 24, 2021
Deals
Aug. 23 Quick Takes: Pfizer, BioNTech look ahead to pediatric data after FDA approval of Comirnaty
Approval for COVID-19 vaccines from Zydus Cadila, Medigen-Dynavax; plus Sabatini fired, Clover’s U.S. beachhead and more
BioCentury | Jun 30, 2021
Product Development
Acrivon debuts with Lilly DDR inhibitor to test proteomics-based companion diagnostics platform
Acrivon launched with a platform for designing proteomics-based companion diagnostics, and a targeted therapy licensed from Eli Lilly and Co. (NYSE:LLY) will become its first test case. Though most
Items per page:
1 - 10 of 373